This Decision Letter sets out the Programme Terms of a Programme

1. Country: Tanzania

2. Programme Payment Grant number: 1217-TZA-10d-Y
3. Performance Payment Grant number: n/a

4. Date of Decision Letter: 16 December 2014

5. Date of the Partnership Framework Agreement: 01 July 2013

6. Programme Title: Health Systems Strengthening (HSS)

7. HSS terms:

   The ultimate aim of HSS support is to ensure increased and sustained immunisation coverage through addressing health systems barriers in Country, as specified in:
   - The relevant Gavi HSS guidelines – please contact Stefano Lazzari at slazzari-external-consultant@gavi.org or Sabrina Clement sclement@gavi.org for the guidelines.
   - The relevant Gavi HSS application form - please contact Stefano Lazzari at slazzari-external-consultant@gavi.org or Sabrina Clement sclement@gavi.org for the form.
   - Country’s approved grant proposal and any responses to the HSS IRC’s request for clarifications.

8. Application of Performance Based Funding (PBF):

   Does PBF apply:
   YES ☒ (starting from 2015)
   NO □

9. Gavi Performance Based Funding

   The HSS cash support shall be subject to Gavi’s performance-based funding (PBF). Under this, the HSS support will be split into two payments: the programmed payment (based on implementation of the approved HSS grant) and the performance-based payment (based on improvements in immunisation outcomes). This means that in the first year, Country will receive 100% of the approved ceiling, or programme budget if different (the initial Annual Amount), as an upfront investment. After the first year, countries will receive 80% of the ceiling, or programme budget if different, based on implementation of the grant, and additional payments will be based on performance on immunisation outcome indicators. Note that countries whose total grant budget would fall below US$3 million are exempt from this 80% rule.

   Country will have the opportunity to receive payments beyond the programme budget amount, for exceptional performance on the same immunisation outcomes. The maximum programmed payment plus performance payment may be up to 150% of the country ceiling.

   Performance payments for a given year will be made the following year, based on performance of the indicators listed and data verification.

Gavi Calculation of Performance Payments for 2013 achievements: N/A
10. Programme Duration\(^\text{16}\): 2012 - 2017

11. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement, if applicable):

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>Total(^\text{17})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Performance payment</td>
<td>N/A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

12. Annual Amounts (subject to the terms of the Partnership Framework Agreement):

<table>
<thead>
<tr>
<th>Programme Year</th>
<th>2012-2014</th>
<th>2015</th>
<th>Total(^\text{18})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Amount ($US)</td>
<td>US$3,786,840</td>
<td>US$3,635,922</td>
<td>US$7,422,762</td>
</tr>
<tr>
<td>Performance Payment ($US)</td>
<td>Not applicable</td>
<td>Not applicable</td>
<td></td>
</tr>
</tbody>
</table>

13. Financial Clarifications: n/a

14. Documents to be delivered for future HSS cash disbursements:

The Country shall deliver the following documents by the specified due dates as part of the conditions for approval and disbursements of the future Annual Amounts.

<table>
<thead>
<tr>
<th>Reports, documents and other deliverables</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Progress Reports (APRs), or equivalent. The APRs, or equivalent, should provide detail on the progress against milestones and targets against baseline data for indicators identified in the proposal, as well as the PBF indicators. The APRs, or equivalent, should also include a financial report on the use of Gavi support for HSS (which could include a joint pooled funding arrangement report, if appropriate) and use of performance payments, which have been endorsed by the Health Sector Coordination Committee (HSCC) or its equivalent.</td>
<td>15 May 2015</td>
</tr>
<tr>
<td>Interim unaudited financial reports. Unless stated otherwise in the existing Aide Memoire between Gavi and the Country, the Country shall deliver interim unaudited financial reports on the HSS cash support no later than 45 days after the end of each 6-month reporting period (15 February for the period covering 1 July - 31 December and 15 August for the period covering 1 January - 30 June). Failure to submit timely reports may affect future funding.</td>
<td>15 February 2015 and 15 August 2015</td>
</tr>
</tbody>
</table>

15. Other conditions: The following terms and conditions shall apply to HSS support.

Cash disbursed under HSS support may not be used to meet Gavi's requirements to co-finance vaccine purchases.

In case the Country wishes to alter the disbursement schedule over the course of the HSS programme, this must be highlighted and justified in the APR, or equivalent, and will be subject to Gavi approval. It is

---

\(^{16}\) This is the entire duration of the programme.

\(^{17}\) This is the total amount endorsed by Gavi for the entire duration of the programme.

\(^{18}\) This is the amount approved by Gavi.
essential that Country’s Health Sector Coordination Committee (or its equivalent) be involved with this process both in its technical process function and its support during implementation and monitoring of the HSS programme proposal. Utilisation of Gavi support stated in this letter will be subject to performance monitoring.

16. Other conditions: The following terms and conditions shall apply to performance payments.

   The performance payments under the performance-based funding shall be used solely for activities to be implemented in the country’s health sector.

   Neither programmed nor performance payments may be used to purchase vaccines or meet Gavi’s requirements to co-finance vaccine purchases, and shall not be used to pay any taxes, customs, duties, toll or other charges imposed on the importation of vaccines and related supplies.

On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
16 December 2014